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Summary Soil-transmitted helminths of the genus Strongyloides (S. fuelleborni and the more
prevalent S. stercoralis) are currently believed to infect an estimated 30—100 million people
worldwide. The health consequences of S. stercoralis infections range from asymptomatic light
infections to chronic symptomatic strongyloidiasis. Uncontrolled multiplication of the parasite
(hyperinfection) and potentially life-threatening dissemination of larvae to all internal organs
is found among individuals with compromised immune system functions. This paper provides
an overview of the current state of the art in relation to diagnostic methods for detecting the
infection, the morbidity caused by the infection and the recommended treatment. It further
discusses some of the reasons why this infection is so neglected and the consequence of this
for the estimated global prevalence. The paper ﬁnally points to the gaps in our knowledge and
future research needs related to this infection. As Strongyloides infections have the potential to
develop into severe disease in certain population subgroups, untreated infections could cause
serious problems in the community. Therefore, we need to carefully investigate this parasite
in order to develop and implement effective control programmes.
© 2009 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights
reserved.
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. Introduction
oil-transmitted helminths of the genus Strongyloides
urrently infect an estimated 30—100 million people
orldwide.1 At least two species parasitize humans —
. fuelleborni and the more prevalent S. stercoralis.2,3
trongyloides fuelleborni is a zoonosis that usually occurs in
on-human primates, but human infections occur in Africa
nd Southeast Asia. Strongyloides stercoralis is an intestinal
ematode that infects humans percutaneously. It is com-
on in many areas where sanitary conditions are poor,4
nd where the climate is warm and humid. However, the
arasite is also endemic in several subtropical and temper-
te regions, e.g. southern areas of the USA, Europe and
apan. The ability of S. stercoralis to replicate within the
ost (autoinfection) leads to persistent infections and can
esult in chronic disease with a wide variation of clinical
anifestations. Uncontrolled multiplication of the parasite
hyperinfection) and potentially life-threatening dissemi-
ation of larvae to all internal organs are found among
ndividuals with compromised immune system functions.
part from parasitizing the vertebrate intestine, the life
ycle of these nematodes can also include one or more
depending on the species) free-living generations, leading
o important epidemiological consequences.
At the Third Global Meeting of the Partners for Parasite
ontrol, held at WHO headquarters in November 2004, it
as recommended that measures for the control of Strongy-
oides should be included in health packages targeting areas
here the infection is endemic.5 Today, more than 4 years
ater, no action has been taken and no speciﬁc measures
ave been implemented. One of the probable reasons is the
ack of even basic data on Strongyloides endemicity and
pidemiology. We also do not know to what extent exist-
ng soil-transmitted helminth and lymphatic ﬁlariasis control
rogrammes affect the epidemiology of Strongyloides, as
he demonstration of this parasite requires special detec-
ion methods, which usually fall outside the scope of these
rogrammes.
As Strongyloides infections have the potential to develop
nto severe disease in certain population subgroups,
ntreated infections could cause serious problems in the
ommunity. We therefore feel that we have to take action
ow and carefully investigate this parasite in order to
evelop and implement effective control programmes.
. Presentation of the parasite
he genus Strongyloides contains more than 50 species with
n almost equally wide range of hosts. At least two species
re known to infect humans.
Strongyloides fuelleborni primarily infects various pri-
ates in Africa and Southeast Asia but has also been found in
umans. Thus, the parasite is zoonotic or, at least, zoonotic
n its origin.6 Strongyloides fuelleborni eggs can be found
n stool and although the question of autoinfection is still
ot resolved, it probably does not occur in persons with
gg-passing infections.6
The cosmopolitan S. stercoralis occurs in over 70 subtrop-
cal and tropical countries, but is also endemic in several
emperate countries where conditions are favourable. For
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xample, S. stercoralis infections are, together with hook-
orm infections, the only ofﬁcially recognized occupational
arasitic health hazard for miners in Germany.7 The para-
ite infects humans, other primates and dogs. Strongyloides
tercoralis has a complex life cycle including a direct, an
utoinfective and a non-parasitic free-living developmen-
al cycle (Figure 1). Only parasitic females are found in
he host where they are embedded in the submucosa of
he duodenum and parthenogenetically produce dozens of
mbryonated eggs a day. These hatch in the gut lumen of the
ost and the ﬁrst-stage larvae are passed out in faeces and
ither develop into infective third-stage larvae or into free-
iving adult males and females. Alternatively, larvae may
evelop to the third stage still within the gastrointestinal
ract and penetrate the intestinal mucosa or perianal skin,
estarting a new infection cycle without ever leaving their
ost. The free-living adults reproduce sexually and the off-
pring develop into infective third-stage larvae. There exists
nly one free-living generation of S. stercoralis.8 Third-stage
arvae are able to penetrate the skin of the human host,
each the lungs via the blood circulation and enter the respi-
atory pathways, from where they migrate upwards through
he trachea to be swallowed and ﬁnally reach the small
ntestine where they mature into adult egg-laying females.
. Diagnosis and global epidemiology of
trongyloides
tandard parasitological diagnostic methods for detecting S.
tercoralis infection are concentration techniques or stool
ulture methods.9 However, these methods are laborious,
ime consuming, and, in the case of stool cultures, need well
rained technicians in order to differentiate S. stercoralis
rom hookworm larvae. Several immunological tests, such
s ELISA, IFAT and Western blot, have also been described
or the diagnosis of strongyloidiasis.10,11 These assays show
ariable sensitivity and speciﬁcity depending on antigen
reparation and immunoglobulin isotypes used, and on the
opulation tested. In speciﬁc target populations, such as
mmigrants to non-endemic regions, serology has proven to
e a valuable tool for screening and for the evaluation of
herapies;12 however, serology seems to lack sufﬁcient sen-
itivity to diagnose recently acquired infections.13 Although
erology seems to have good negative predictive value if
sed in endemic areas,14 speciﬁcity appears to be more
roblematic as pronounced crossreactivity is observed with
ther helminths, especially ﬁlaria. Speciﬁc detection of
trongyloides DNA in human stool samples by real-time PCR
as recently been suggested to be a promising alternative
iagnostic approach, but needs further exploration.
The current estimate of 30—100 million Strongyloides
nfections in humans1 is likely to be too low. To achieve a
eliable estimate of the true prevalence of infection, sev-
ral stool samples should be collected over consecutive days
nd tested by various diagnostic methods. In a population-
ased study in China, combining diagnostic approaches and
epeated examinations resulted in an unexpectedly high
revalence of 11.7%.15 Using a similar approach, Strongy-
oides was shown to be a very common parasite (prevalence
0.6%) in northern Ghana.16 In a recent study in Mozambique
unpublished data) careful examinations of direct smears
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and formol ether concentration sediments showed 9% and
12% of the population to be infected, while a combination of
culture, Baermann concentration and PCR revealed a preva-
lence of 48%.
4. Morbidity caused by Strongyloides
The health consequences of S. stercoralis infections range
from asymptomatic light infections to chronic symptomatic
strongyloidiasis involving anything from mild gastrointesti-
nal morbidity to severe life-threatening conditions. The
pathology due to chronic uncomplicated S. stercoralis
infections includes pruritus, skin eruptions, larva currens,
abdominal pain, diarrhoea, nausea and weight loss.17
The most severe effects of Strongyloides infections
occur in patients receiving immunosuppressive therapy with
corticosteroids.18—21 In these patients, the immune system
is no longer able to keep the larvae emerging from the
autoinfective cycle under control, resulting in hyperinfec-
tion affecting the proper functioning of the gastrointestinal
tract or the dissemination of larvae to multiple organs
including the brain. Such massive infections may lead
to life-threatening conditions with pneumonia, meningitis,
s
s
i
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tercoralis. Drawing by A.M. Polderman.
epticaemia and intestinal obstruction.17 The mortality rate
f disseminated infections has been estimated to be as
igh as 87%.22 Immunosuppression with Cyclosporine A is not
nown to have such devastating effects.23
In many parts of the world strongyloidiasis occurs
ogether with HIV/AIDS, but co-infection has not been found
o be associated with higher S. stercoralis prevalence or
he development of hyperinfections.24 However, S. sterco-
alis hyperinfection has been described in AIDS patients as
art of the immune reconstitution syndrome after starting
ighly active antiretroviral therapy.25 In a study in Tanzania
nvolving HIV-infected pregnant women, S. stercoralis infec-
ion was associated with a higher risk of low birth weight,
hich is the single most important factor for high infant
ortality.26 In contrast, human T cell lymphotropic virus
ype 1 infection is strongly associated with a higher S. ster-
oralis prevalence as well as with an increased incidence of
yperinfection.27—29
Although there is a pronounced association between dis-
eminated strongyloidiasis and suppression of the immune
ystem, there are also a signiﬁcant number of fatal cases
n the literature which could not be linked to any known
mpairment of the immune system.30 They have tenta-
ively been explained by host factors of intestinal parasite
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ontrol which act at the interface between the host and
he parasite, i.e. the mucosa of the gastrointestinal tract,
nd are mediated by some local control mechanisms. In
mpoverished populations where subclinical malnutrition is
ommon, profound morphological disruption of the small
ntestinal mucosa is highly prevalent. These changes may
ave functional repercussions on the hosts’ ability to ﬁght
ff infections.31 This hypothesis might also explain why
evere complicated strongyloidiasis with no clinical evi-
ence of immunosuppression is more frequently observed in
ersons living in developing countries. Malnutrition, one of
he most important causes of immunodeﬁciency in devel-
ping countries, was found to be associated with severe
trongyloidiasis.30 Autoimmune diseases such as diabetes
ellitus may exacerbate complications and impact on the
everity of Strongyloides infection.32
. Treatment
he recommended treatment for strongyloidiasis is either
vermectin (200g/kg body weight in a single dose) or alben-
azole (400mg daily for 3 days).33,34 In a study in Zanzibar,
he effect of the two regimens was compared. A cure rate
f 82.9% was achieved for ivermectin while three doses of
lbendazole cured 45.0% of the infected individuals.33
Most helminth control programmes employ mass drug
dministration as their principal tool; hence, they offer
reatment without prior diagnosis. For control of soil-
ransmitted helminths, the target population is usually
choolchildren, but regular (e.g. annual) mass treatment
f entire communities using one of the four common ante-
elminthic compounds included in the WHO model list of
ssential drugs is recommended wherever the prevalence is
50%.35 In areas where schistosomiasis is co-endemic with
oil-transmitted helminths, praziquantel (40mg/kg body
eight) is co-administered with albendazole (400mg single
ose) or mebendazole (500mg single dose), again mainly
o schoolchildren. In areas targeted for lymphatic ﬁlaria-
is control, albendazole (400mg single dose) and ivermectin
150g/kg body weight) or diethylcarbamazine (where
nchocerciasis is not endemic) are given to the entire popu-
ation above 4 years old. To minimize costs, collaboration
etween the programmes is encouraged and is currently
mplemented in many countries.36 Thus, in areas where
chistosomiasis and lymphatic ﬁlariasis are both endemic,
lbendazole plus ivermectin followed by praziquantel 1
eek later is the preferred regimen. Among all these reg-
mens, only the distribution of ivermectin in the frame of
ymphatic ﬁlariasis control can be expected to result in a
eaningful reduction of the prevalence of S. stercoralis. In
reas with strongyloidiasis, targeted chemotherapy of high
isk groups should be considered. As a minimum, all patients
cheduled to receive corticosteroids should be given preven-
ive anthelminthic treatment if they live in or have travelled
n potential endemic areas.21
. Why is Strongyloides infection so
eglected?
he prevalence of S. stercoralis is thought to be severely
nderestimated due to the low sensitivity of the currently
n
n
f
b
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vailable diagnostic tools and a dearth of specialized sur-
eys. The most widely used method for the identiﬁcation
f human intestinal helminth infections in developing coun-
ries, i.e. the Kato-Katz technique, detects eggs in faeces
ut fails to demonstrate larvae. The performance of stan-
ard procedures like formol-ether concentration methods
s limited by the low concentration of larval stages in fae-
al specimens in chronic strongyloidiasis. Parasite-speciﬁc
oncentration methods like the Baermann technique and
ulture methods9 are much more sensitive, but even with
he use of these methods many light (chronic) infections
re missed. Therefore, S. stercoralis infections are seldom
etected and many areas without information persist on the
lobal S. stercoralis distribution map. Thus, the epidemio-
ogical knowledge regarding this parasite is patchy at best.
nly in patients with disseminated strongyloidiasis may large
umbers of larvae be demonstrated in faeces, sputum, urine
nd lung ﬂuids as well as in organ biopsies. Chronic uncom-
licated S. stercoralis infections also cause subtle pathology,
hich is non-speciﬁc for this infection. Therefore, the infec-
ion often remains undiagnosed.
. Gaps in knowledge — future research needs
t is encouraging that the Partners for Parasite Control rec-
mmend that Strongyloides infections should be included
n health packages wherever it is endemic.5 Today, the
nfection is only targeted passively — and, presumably, not
ffectively — in the framework of integrated helminth con-
rol programmes. The notion that an additional parasite can
e controlled by these programmes may lead to a better
ost-effectiveness rating of such programmes and, once the
pidemiology and public health signiﬁcance of strongyloidi-
sis has been determined, to better acceptance. Thus, the
peciﬁc impact of these programmes on S. stercoralis awaits
areful evaluation. For example, we do not know how the
urrently used drug regimes inﬂuence the course of infec-
ion. The drug dosages are suboptimal especially in areas
here lymphatic ﬁlariasis is not endemic and therefore iver-
ectin is not used. One dose of albendazole will usually not
lear the infection. This is of particular concern because
he parasite replicates within the host. The residual para-
ites may represent a proportion of the population which
s more refractory to the drug. It is therefore possible that
esistance will develop and become established.
Many epidemiological aspects of Strongyloides infection
re unknown or only poorly understood. We do not know
n detail where Strongyloides is endemic, which prevalence
ates and intensities can typically be expected in different
ettings and populations, the zoonotic aspects, geographi-
al variations, e.g. in transmission and clinical presentation,
ost immunity and the risk factors for dissemination, and
ocial, cultural, ecological and environmental aspects.
Improvement and simpliﬁcation is needed in the con-
entional diagnostic methods, to facilitate epidemiological
tudies of S. stercoralis in the ﬁeld. There also is an urgent
eed to employ modern molecular methods to improve diag-
osis and for the differentiation between species and strains
rom different hosts and geographical origin. It should also
e established if we are dealing with a species complex or
learly deﬁned biological species.
Strongyloidiasis
Little is known about the true clinical relevance of
Strongyloides infections, the symptoms associated with
different infection patterns, the association between
Strongyloides and other infectious diseases, and of the
relationship between severe infections and autoimmune dis-
eases such as diabetes. The relevance of malnutrition for
Strongyloides, especially among children, and the effects
of the resulting state on the clinical outcome of S. sterco-
ralis infection as well as implications for pregnant women
still need to be revealed.
It is uncommon for helminths to kill their host and in
healthy individuals, S. stercoralis usually causes little or
‘only’ subtle pathology, allowing the infection to remain
undiagnosed — and untreated — for years. Thus, the par-
asite can persist in the host, perpetuating parasite dispersal
and the risk of infection among the community. Given the
tendency to develop severe disease in certain population
subgroups, S. stercoralis is of major public health concern.
Furthermore, since the use of immunosuppressive therapy
becomes increasingly common in transition economies like
China, India, Southeast Asia and Latin America, Strongy-
loides could cause serious problems in the future if we do
not take action now. We need to carefully investigate this
parasite, develop control programmes and implement them
where appropriate.
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